Table 2. Outcomes of included studies.
| Studies | TXA intervention | Blood loss (ml) | Max Hb drop | Transfusion rate | Incidence of thromboembolic complications |
|---|---|---|---|---|---|
| Xie 2015 | IV-TXA | 878.0±210 | 3.4±0.8 | 3(4.3%) | 1 |
| Combined TXA | 776.8±189.0 | 3.0±0.8 | 0(0%) | 2 | |
| Wu 2016 | IV-TXA | 1794.6 ± 162.6 | 4.5±0.7 | 19(45.2%) | 0 |
| Combined TXA | 1326.9 ±143.2 | 3.7±0.6 | 9(21.4%) | 1 | |
| Zeng 2016 | IV-TXA | 1002.6 ± 366.8 | NR | 8(16%) | 2 |
| Combined TXA | 835.5 ± 343.5 | NR | 1(2%) | 2 | |
| Zhang 2015 | IV-TXA | 1019 ± 137 | NR | 9(26.5%) | 0 |
| Combined TXA | 787 ± 110 | NR | 5(14.7%) | 0 | |
| Sun 2016 | IV-TXA | 1150 ± 310 | NR | 9(26.5%) | 2 |
| Combined TXA | 780 ± 270 | NR | 3(9.7%) | 1 |
NR: Not report; I: Intravenous group; T: Topical group